LigoLab Information System is an American software company that provides software and laboratory operating systems for clinical laboratories.[1] LigoLab develops and distributes the software tool TestDirectly, which is used for COVID-19 testing. It is based in Glendale, California.[2][3]
History
LigoLab was co-founded in 2006 by Suren Avunjian and Edward Kharatian.[4][5] Prior to founding LigoLab, Avunjian was Director of IT for Health Line Clinical Laboratories, which was eventually acquired by Labcorp.[6]
In March 2020, LigoLab also provided LIS (laboratory information system) support for laboratories in several states including California, New York, and Washington that were conducting high-volume COVID-19 tests. In this capacity, LigoLab integrated its LIS & RCM Operating Platform with multiple instruments for COVID-19 testing.[9]
LigoLab formed a partnership with Northwest Pathology and the Florida Department of Health through TestDirectly in June 2020. The partnership was formed to carry out COVID-19 testing on long-term care residents and staff in the state of Florida.[10][11]
LigoLab's LIS & RCM Operating Platform was used by clinical laboratory Atlas Genomics to detect the first case of the B.1.1.7 variant of SARS-CoV-2 in King County, Washington in February 2021.[12] In March 2021, LigoLab added LIS functionality to its TestDirectly platform.[13]
As of November 2021, the company had 130 clinical laboratories in the United States in its network.[14]
Software
LigoLab provides an LIS & RCM Operating Platform that integrates administrative, technical, and financial operations in a laboratory environment.[15] The platform also enables automation of laboratory processes and combining LIS and RCM workflows.[16] In 2020, the platform was integrated with multiple COVID-19 testing instruments from companies such as Roche, Thermo Fisher Scientific, and QIAGEN. LigoLab's LIS has been used by laboratories such as Reditus Laboratories.[17]
LigoLab's TestDirectly software provides a web-based platform that links patients and governmental organizations with laboratories, doctors, and collection centers for direct-to-consumer COVID-19 testing, including at-home specimen collection.[18][19]
De Rienzo, Assunta; Cook, Robert W.; Wilkinson, Jeff; Gustafson, Corinne E.; Amin, Waqas; Johnson, Clare E.; Oelschlager, Kristen M.; Maetzold, Derek J.; Stone, John F.; Feldman, Michael D.; Becich, Michael J.; Yeap, Beow Y.; Richards, William G.; Bueno, Raphael (2017-01-01), "Validation of a Gene Expression Test for Mesothelioma Prognosis in Formalin-Fixed Paraffin-Embedded Tissues", The Journal of Molecular Diagnostics, 19 (1): 65–71, doi:10.1016/j.jmoldx.2016.07.011, PMC5225306, PMID27863259
